By: Ryan Scott, Chris Ryan
Taletrectinib adipate is approved for ROS1-positive NSCLC in patients previously treated with ROS1 TKIs, based on the TRUST-I trial results.
Ryan Scott is a journalist at /Film. With over a decade of experience primarily in the pop culture space, he covers a wide range of topics including movies, TV, and gaming, while also delving into themes related to healthcare and alternative medicine. Ryan has been featured in numerous respected publications such as Runner's World Magazine, Fangoria, and Inverse.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Ryan Scott's coverage includes a mix of entertainment news and gaming, with a focus on box office performance, movie franchises, and industry trends. Pitches to Ryan should highlight insights into box office performances, movie franchises or gaming-related developments.
Given the prevalence of data citations in his articles, he would likely appreciate pitches supported by relevant statistics or research related to box office performance trends or audience preferences in movies and gaming.
As Ryan does not have a specific geographic focus but covers global entertainment news, pitches with an international perspective on box office successes and failures across different regions could be well-received.
This information evolves through artificial intelligence and human feedback. Improve this profile .